Tore Saxne
About
In The Last Decade
Tore Saxne
198 papers receiving 11.7k citations
Peers
Comparison fields: 5 of 148
- Rheumatology 8.0k
- Immunology 2.8k
- Surgery 1.8k
- Hematology 1.7k
- Molecular Biology 1.6k
Countries citing papers authored by Tore Saxne
This map shows the geographic impact of Tore Saxne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tore Saxne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tore Saxne more than expected).
Fields of papers citing papers by Tore Saxne
This network shows the impact of papers produced by Tore Saxne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tore Saxne. The network helps show where Tore Saxne may publish in the future.
Co-authorship network of co-authors of Tore Saxne
This figure shows the co-authorship network connecting the top 25 collaborators of Tore Saxne. A scholar is included among the top collaborators of Tore Saxne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tore Saxne. Tore Saxne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 3 | |
| 3 | 34 | |
| 4 | 69 | |
| 5 | Vad är reumatologi? | 0 |
| 6 | 78 | |
| 7 | Non-collagenous Proteins; Glycoproteins and related proteins | 2 |
| 8 | TNF-antagonist treatment and risk of hospitalisation for cardiovascular disease. Results from the National Swedish Monitoring-Program for Biologies in Ra (ARTIS). | 0 |
| 9 | TNF-antagonist treatment and risk of hospitalisation for infection. Results from the National Swedish Monitoring-Program for Biologics in RA (ARTIS). | 1 |
| 10 | 163 | |
| 11 | 297 | |
| 12 | No increase of severe infections in RA patients treated with TNF-blockers | 3 |
| 13 | Risk of tuberculosis in rheumatoid arthritis and following anti-TNF treatment. Preliminary results of an ongoing Swedish monitoring-programme of biologics in RA | 3 |
| 14 | Risk of cardiovascular morbidity and mortality following TNF-blockade. Preliminary results of an ongoing Swedish monitoring-programme of biologics in RA | 2 |
| 15 | Safety and efficacy of adalimumab in arthritis patients previously treated with another biologic agent | 2 |
| 16 | A national database for co-morbidity in RA to evaluate drug safety. Solid cancers in RA and following anti-TNF treatment | 0 |
| 17 | Risk for lymphomas following TNF-blockade. Comparisons with a nationwide co-morbidity database | 1 |
| 18 | Molecular markers for assessment of cartilage damage in rheumatoid arthritis | 11 |
| 19 | Matrix Glycoproteins and Proteoglycans in Cartilage | 5 |
| 20 | Connective tissue macromolecules as markers for tissue processes in joint disease. | 11 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.